Biweekly irinotecan plus cisplatin (BIRIP) versus irinotecan alone (IRI) after S-1-based chemotherapy failure in patients with advanced gastric cancer (AGC): Final analysis of a randomised phase Ill trial (TCOG GI-0801/BIRIP trial)
EUROPEAN JOURNAL OF CANCER（2013）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要